



Final Appraisal Recommendation

Advice No: 2613 – October 2013

**Tegafur/gimeracil/oteracil (Teysuno[®]▼) 15 mg/4.35 mg/11.8 mg
and 20 mg/5.8 mg/15.8 mg capsules**

Submission by Nordic Pharma UK Ltd

Recommendation of AWMSG

Tegafur/gimeracil/oteracil (Teysuno[®]▼) is recommended as an option for restricted use within NHS Wales in adults for the treatment of advanced gastric cancer when given in combination with cisplatin, when standard triplet therapy is not suitable.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 928), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Nordic Pharma UK Ltd
Date of first issue	October 2013
Last reviewed	December 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2613:
Tegafur/gimeracil/oteracil (Teysuno[®]▼) 15 mg/4.35 mg/11.8 mg and 20 mg/5.8 mg/
15.8 mg capsules. October 2013.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.